Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» MaaT013
MaaT013
MaaT Pharma Phase III microbiome trial hits endpoints as stock soar
Clinical Trials Arena
Thu, 01/9/25 - 11:05 am
MaaT Pharma
microbiome
clinical trials
MaaT013
MaaT Pharma’s GvHD drug boasts 18-month overall survival improvement
Clinical Trials Arena
Mon, 04/15/24 - 11:20 am
MaaT Pharma
MaaT013
graft vs host disease
clinical trials
Microbiome-based treatment shows potential in graft-versus-host disease
Biopharma Reporter
Tue, 12/19/23 - 10:16 am
MaaT Pharma
microbiome
graft vs host disease
MaaT013
Is MaaT back? After 18 months on hold, microbiome biotech sees end to impasse with FDA
Fierce Biotech
Fri, 02/3/23 - 10:55 am
MaaT Pharma
microbiome
FDA
fecal microbiome
MaaT013
Microbiome Report for Week Ending 4/13/19
CP Wire
Thu, 04/18/19 - 10:33 pm
MaaT Pharma
MaaT013
aGvHD
Second Genome
SkinBio Therapeutics
Azitram AZT-02
Netherton Syndrome
Microbiome Report for Week Ending 4/13/19
Thu, 04/18/19 - 10:31 pm
MaaT Pharma
MaaT013
aGvHD
Second Genome
SkinBio Therapeutics
Azitram AZT-02
Netherton Syndrome
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Ph II Study in Acute GvHD
CP Wire
Wed, 04/10/19 - 11:31 pm
MaaT Pharma
graft vs host disease
MaaT013
MaaT Pharma Announces Second Positive DSMB Safety Assessment of Ph II Study in Acute GvHD
Wed, 04/10/19 - 09:24 pm
MaaT Pharma
graft vs host disease
MaaT013